The large majority of older patients with autoimmune Graves'hyperthyroidism and atrial fibrillation (AF) have coexisting activating autoantibodies (AA) to the beta1-adrenergic (B1AR) and M2 muscarinic receptors (M2R). Adrenergic and muscarinic agonists are known to enhance the likelihood for developing AF. HYPOTHESIS: AA in the aging thyrotoxic heart facilitates and/or causes AF. We have demonstrated AABAR) in 94% and AAM2R in 88%;and both autoantibodies in 83% in Graves'hyperthyroidism + AF compared to 10% of Graves'patients in normal sinus rhythm (P<0.001). All patients with AF had at least one of the two AA. These autoantibodies altered electrophysiological activity in pulmonary vein atrial sleeve cells such as predisposes to AF in experimental models;supporting our concept that elevated AABAR and AAM2R as well as thyroid hormone are major risk factors for AF. PROPOSAL: We will use translational and mechanistic studies to examine the electrophysiological interrelationships of thyroid hormone, age and activating autoantibodies as a cause of AF. METHODS: (Spec.
Aim A) Expansion of epidemiological studies to identify the prevalence and function of autoantibodies in non-Graves" hyperthyroidism and AF;(Spec.
Aim Bi) Identify age and thyroid hormone dependent triggering of ectopic action potentials in the presence of target-specific autonomic AA in a canine pulmonary vein atrial sleeve tissue preparation in vitro;(Spec.
Aim Bii) Study the development of AF (by ECG telemetry) in young (6 mo) and old (>5yrs) rabbits immunized to produce target-specific AAB1AR and/or AAM2R without and with thyroid hormone. We will then use sophisticated electrophysiological studies incorporating right atrial ganglia stimulation to measure the pulmonary vein atrial sleeve cell threshold for induction of AF. This model will determine the combined effects of AABAR and AAM2R on the atrial substrate for AF. METHODS also include a FRET-based micro-cAMP assay to examine the allosteric effects of AA. This assay will assist in determining whether these AA act as agonists and whether they also serve as partial antagonists to their normally operative orthosteric ligands. Our studies are NOVEL in that they will identify a spectrum of activating autoantibodies in the heart and demonstrate their role in immune-mediated mechanism(s) leading to AF in hyperthyroidism. Our data are relevant not only to hyperthyroidism but will also lead to a better understanding of these mechanisms in other and more common forms of AF which frequently coexist with AA. POTENTIAL IMPACT ON VETERANS HEALTH CARE: AF is an important risk factor for stroke and heart failure in our aging veteran population and leads to increased mortality and morbidity. The present study addresses this issue and may permit identification of future therapeutic options.

Public Health Relevance

The presence of an irregular heart rate (atrial fibrillation) is associated with 1/3 of the strokes in the general population and is related to decreased cardiac function and with increasing age. Atrial fibrillation is a significant source of strokes and heart failure in the veteran population. An overactive thyroid in older veterans frequently causes atrial fibrillation and requires blood thinning, careful medical attention and still does not always prevent strokes. We have discovered certain antibodies are directed toward the heart and are present in almost 100% of these patients with atrial fibrillation. They appear to contribute to atrial fibrillation and make it difficult for treatment. The proposed studies will examine the role that these signaling antibodies have with excess thyroid hormone and aging to cause the irregular rhythm. Our studies are directed toward establishing this association with atrial fibrillation and to develop future preventative measures and treatment.

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
5I01CX000381-02
Application #
8245564
Study Section
Cardiovascular Studies A (CARA)
Project Start
2010-10-01
Project End
2013-09-30
Budget Start
2011-10-01
Budget End
2012-09-30
Support Year
2
Fiscal Year
2012
Total Cost
Indirect Cost
Name
Oklahoma City VA Medical Center
Department
Type
DUNS #
020719316
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104